Industry Explorers Blaze On

Industry Explorers Blaze On is a series of interviews with senior executives who played a historical role in drug discovery and development and are still active in the biopharma industry.

  • Industry Explorers Blaze On: Anna Protopapas

    Her mother was the first woman of her village in Cyprus to go to high school. Anna Protopapas shared her mother’s drive to bypass all barriers, and she now runs the biopharma company Mersana, after many years in the leadership of Millennium and Takeda.

  • Industry Explorers Blaze On: Pat Andrews

    A look at the 26-year career of Pat Andrews, CEO of Boston Biomedical, who went from Big Pharma to small biotech.

  • Industry Explorers Blaze On: Deborah Dunsire

    Deborah Dunsire has lived and worked in a world driven by commercial drug development for three decades. She’s worked for Big Pharmas such as Novartis and Sandoz and is now trying her hand at managing a small pharma as president & CEO of XTuit. For sure, she’s been a pioneer — but she’s not done yet.

  • Industry Explorers Blaze On: Leading Business With Science — Part 2

    We continue the story of Geert Cauwenbergh whose nearly 40 years in the industry included work with Paul Janssen as well as being a startup entrepreneur with RXi Pharmaceuticals.

  • Leading Business With Science: Geert Cauwenbergh of RXi

    Geert Cauwenbergh now can look back at his almost four decades in the industry — from his formative years working with Paul Janssen building a small company into a global phenomenon, to his later years as a startup entrepreneur with RXi — and reflect on how most of it has turned upon a snap decision.

  • Abbey Meyers: Did The Pioneer Of Orphan Drugs Spark Biopharma?

    By the time Abbey Meyers, founder of the National Organization for Rare Disorders (NORD) and chief architect of the ODA, wrote her letter to me a few years later, the paradoxical conflict of orphan-drug availability versus price had become obvious.

  • David Hale: How The Journey To Entrepreneurial Biotech Begins

    These are the stories of longtime leaders, still active in the industry, sharing their historical perspectives on innovation in the life sciences industry. This month: Why David Hale is considered an icon of entrepreneurial biotech.

  • Industry Explorers Blaze On: R&D Veteran William Comer Of NeuroGenetic

    The chairman of Bristol-Myers summoned the head of R&D into his office. “Bill, go down and check out the ruckus on the street,” he said. “Something about our new AIDS drug.” When Dr. William Comer exited the front door of the company’s New York City headquarters, he saw a small group of men marching around on the sidewalk, holding signs, blowing trumpets, beating drums, and chanting loudly.


  • What 4 Biopharma CFOs Think About The Future Of Remote Work

    While we touch on remote work in Life Science Leader’s annual outlook issue, the responses in this article from four biopharmaceutical CFOs to questions on the subject shed additional light on the challenge that lies ahead for employers.

  • Where Does Biopharma’s Future Reside Beyond Boston And San Francisco?

    Two metropolitan areas tend to dominate the discussion when it comes to key biopharmaceutical industry hubs within the United States — Boston and San Francisco. And while these two cities have certainly earned their biopharma bragging rights over the years, one has to wonder how long that will continue. Afterall, just a few years ago biopharmaceutical executives noted it becoming increasingly difficult to attract top talent, as candidates cited “too crowded,” “too expensive,” and a host of other reasons behind their unwillingness to move to places like Boston and San Francisco. But does location (for many roles) even still apply?

  • Why Treat The Eye Through The Nose?

    Jeffrey Nau, Ph.D., president and CEO of Oyster Point Pharma and subject of upcoming feature in Life Science Leader, explains the scientific rationale behind treating dry eye disease (DED) using nasal spray as a method of delivery.